|
|
OJHAS Vol. 8, Issue 2: (2009
Apr-Jun) |
|
|
Primary Non-Hodgkin's Malignant
Lymphoma of the Sinonasal Tract |
|
Bist SS, Assistant Professor, Saurabh Varshney, Professor & Head, Rakesh Kumar
Singh, Associate Professor, Sanjeev
Bhagat, Assistant Professor, Nitin
Gupta, Assistant Professor, Department of ENT,
Himalayan Institute of Medical Sciences, HIHT University, Jolly Grant, Doiwala, Dehradun, Uttarakhand, India - 248140 |
|
|
|
|
|
|
|
|
|
Address For Correspondence |
Dr. S.S. Bist, Assistant
Professor (E.N.T), Himalayan Institute
of Medical Sciences HIHT University,
Jolly Grant, Doiwala Dehradun, Uttarakhand
- 248140
E-mail:
sampanbist@yahoo.com |
|
|
|
|
Bist SS, Varshney S, Singh RK, Bhagat S, Gupta N. Primary Non-Hodgkin's malignant
lymphoma of the sinonasal tract Online J Health Allied Scs.
2009;8(2):9 |
|
|
Submitted: Jun 5, 2009; Accepted
Jul 20, 2009 Published: Sep 8, 2009 |
|
|
|
|
|
|
|
|
Abstract: |
Primary non-Hodgkin’s
lymphomas (NHL) of the sinonasal tract are rather uncommon entities.
Morphologically and radiographically, sinonasal lymphomas are difficult
to distinguish from other malignant neoplasms or non- neoplastic processes.
They have a variable presentation from fulminant destructive manifestations
to chronic indolent type of disease and may mimic as carcinomas and
invasive fungal infection respectively. We report a case of primary
NHL involving sinonasal tract in elderly female, which was clinically
and radiologically mimicking as sinonasal malignany and was proven as
NHL on histological examination and confirmed by immunohistochemistry.
A high index of suspicion, appropriate histopathological examination
and immunohistochemistry is necessary to differentiate sinonasal lymphomas
from other possibilities. Failure to do so may miss the diagnosis and
delay appropriate treatment.
Key Words: Sinonasal
lymphoma, Non Hodgkins lymphoma, Immunohistochemistry
|
|
Lymphomas represent a group of malignant
neoplasms of lympho-reticular origin which are subdivided into Hodgkin’s
and Non-Hodgkin’s lymphomas (NHL).1
Approximately 3 to 5% of malignant neoplasms are lymphomas, and 60%
of these are NHL.2 NHL predominates in all areas of the body
including the head and neck. Both types originate most commonly within
a lymph node. Extra nodal involvement does occur and is more common
for NHL. Primary NHL arising in the head and neck area accounts for
10% of all NHL and 30% of extra nodal NHL.3 According to REAL (Revised European-American Lymphoma)
classification 1994, NHL is a heterogeneous group of diseases with peculiar,
morphological, phenotypic and molecular features (B-cell, T-cell and
putative natural killer (NK)-cell neoplasm’s).4
Unlike other classifications, the REAL classification does not distinguish
these tumors as being high or low grade, since it is recognized that
each entity has its own characteristic pattern of behavior.5
Common primary extra nodal sites of lymphomas include liver, soft tissue,
dura, bone, stomach, intestine, bone marrow and others. The nasal cavities and paranasal sinuses are rarely affected by primary
NHL. Geographic factors play a role in the frequency and histological
subtype of NHL of the sinonasal tract. In western populations, sinonasal
NHL approximates 0.2% to 1.6% of all NHL, which is B-cell subtype predominant,
more common in elderly, and primary located in the paranasal sinuses.2
In Asian countries, the incidence is higher, about 2.6 to 6.7% of all
NHL and the T-cell subtype is the predominant form. In contrast with
those in the western world, these lymphomas are more common at younger
ages, primarily located in the nasal cavity, and strongly associated
with the Epstein –Barr virus.6
An early diagnosis of primary NHL of the sinonasal tract is unusual
because such a lesion develops in an anatomic space and expands toward
the sinus or nasal cavity, usually causing no symptoms at the early
stages. Only after reaching a considerable size and involving adjacent
anatomic structures do the presenting symptoms appear and they may masquerade
as other nasal or head and neck diseases. NHL of the sinonasal tract
is an important cause of destructive lesions of the nose and midface;
their course progresses slowly but relentlessly. A systematic attempt
to determine the histological and immunological category of the lymphoma
is necessary, since new modalities of treatment are now available that
are neoplasm specific. We hereby present a case of primary sinonasal
NHL and will be discussing the significance of appropriate histopathological
and immunohistochemical analysis for confirmation of diagnosis before
starting the treatment.
A 68-years-old
female presented with complaint of left nasal obstruction and purulent
nasal discharge for 8 months along with swelling around left lower eyelid
since 2 months. The patient was referred to our hospital as a suspected
case of sinonasal malignancy. Patient had a history of headache, mild
epistaxis and purulent postnasal discharge. The patient had no history
of double vision, loss of consciousness and neurological deficit. Anterior
rhinoscopic examination revealed smooth vascular mass filling the left
nasal cavity completely and widening the anterior nares. On probing
it was sensitive, firm and bleeds on touch. The patient had oedema of
lower eye lid with palpebral hyperemia but no proptosis or restricted
eye movements were noted. A diagnostic nasal endoscopy (Fig.1) did not
reveal any additional findings and endoscope could not be negotiated
on the left side beyond the swelling. Rest of the ENT and systemic examination
were normal.
|
Figure 1: Nasal endoscopy showing
smooth pinkish mass completely filling the left nasal cavity |
Contrast enhancement computed tomography (CECT) revealed
a mildly enhancing soft-tissue density lesion with interspersed hyperdensity
filling the left nasal cavity, maxillary antrum, ethmoid and choana.
There was a widening of maxillary hiatus with focal areas of erosion
of roof of maxillary antrum and medial orbital wall with minimal extracoanal
extension into left orbit (Fig.2). CECT report was suggestive of long
standing antrochoanal polyposis with fungal component or malignancy.
|
|
|
Figure 2: CT scan (Axial &
Coronal) shows an enhancing soft-tissue mass occupying the left nasal
cavity along with maxillary and ethmoid sinuses. |
Clinico-radiologically a provisional diagnosis of carcinoma was made.
The patient had previously undergone fine needle aspiration cytology
of the lesion elsewhere and was suggestive of malignant lesion. For
the confirmation of the diagnosis, biopsy under local anaesthesia from
appropriate site was done. Histological analysis revealed a highly cellular
tumor with dense sheets of compactly arranged cells with scanty cytoplasm
and hyperchromatic nuclei suggestive of a malignant lymphoma or poorly
differentiated carcinoma and immunohistochemisty was advised to confirm the diagnosis. Immunohistochemistry
revealed that the specimen was strongly positive for the leukocyte common
antigen CD45, which is diagnostic of B cell NHL. As staging investigations
revealed no other focus, a primary Non –Hodgkin’s malignant lymphoma
of the sinonasal tract was diagnosed and was staged as IE after a complete
systemic workup. The patient was subsequently planned for chemoradiation.
The patient underwent 6 cycles of CHOP regimen (cyclophosphamide, adriamycin,
vincristine and prednisone) and after completion of chemotherapy CT
scan showed significant regression of the tumor mass (Fig.3a). Patient
was subsequently followed by involved field radiotherapy (40 Gy) without
significant side effects, which resulted in full regression of tumor.
On follow-up at 1 year there is no evidence of recurrence on nasal endoscopy
(Fig.3b). The patient is still under regular follow up.
|
|
|
Figure 3: (a) CT scan (Axial)
after completion of chemotherapy shows significant regression of the
tumor mass. (b) 1 year after completion of chemoradiation endoscopy
shows complete regression of the tumor mass. |
Lymphomas of
the sinonasal tract are known to represent a heterogeneous group of
neoplasms.7 The disease has been given several names, including
midline granuloma syndrome, lethal midline granuloma, polymorphic reticulosis
and midline destructive granuloma. These terms are no longer acceptable,
as most, if not all, of these lesions have been proven to be lymphomas.
The classification of these lymphomas continues to defy the efforts
of lymphoma experts. The inclusion of all sinonasal lymphomas into one
category has been attempted before. A consensus meeting of lymphoma experts from around the world attempting
to define lymphomas of the sinonasal tract concluded that these tumors
have very characteristic morphological, immunophenotypic and molecular
characteristics. Studies have indicated a predominance of T-cell lymphoma
in the nasal cavity, while most paranasal lymphomas are B-cell type.3
Nasal T cell lymphomas usually spread from their site of origin in the
nasal cavity and invade adjacent structures via palatine necrosis. T
cell lymphomas are characterized by progressive ulceration and necrosis,
which are not typical of B cell lymphomas.7 They are also
characterized by their angiotropism or angiocentricity, as tumor cells
infiltrate and destroy blood vessel walls and cause variable degrees
of geographic necrosis.8 Numerous studies have shown that
patients with T and NK cell lymphomas of the sinonasal area have a high
incidence of Epstein-Barr virus (EBV) infection.8 It
is unclear what role EBV plays in the origin of sinonasal lymphomas,
but one possible explanation involves clonal proliferation in response
to viral stimulation. Sinonasal B cell lymphomas primarily involve the
maxillary and ethmoid sinuses, and they extend locally to involve the
orbit, cheek, and anterior cranial fossa. They do not usually manifest
angioinvasion and so vascular necrosis does not occur.7
In our patient, however, the tumor appeared to have originated in the
nasal cavity and then spread to the paranasal sinuses. Sinonasal lymphoma
can occur over a wide range of ages, peaking in the sixth decade, with
male predominance. Sinonasal lymphomas are usually submucosal and on
gross appearance differ from squamous cell carcinomas, which are usually
ulcerative. The most common presenting symptoms of sinonasal lymphomas
are nasal obstruction, discharge, epistaxis, headache and unilateral
facial, cheek, or nasal swelling.1 Patients may also show
signs of infiltration, such as proptosis, diplopia, blurred vision and
cranial nerve palsies secondary to orbital or skull base extension.
Dissemination is infrequent, but when it does occur, it typically involves
other extranodal sites. Obtaining a histological diagnosis is difficult;
in some cases several biopsies are required because of the severe local
inflammatory infiltrate and the presence of large areas of necrosis
that impaired visualization of neoplastic cells. Because malignant lymphomas
are associated with surface crusting, widespread necrosis, and inflammation,
they were once considered to be inflammatory lesions. It was not until
the introduction of immunohistochemistry that most of these lesions
were found to be malignant lymphomas. Based on immunohistochemistry,
the three phenotypes of malignant lymphomas are T cell, natural killer
(NK) cell and B cell. These lymphoid cells stained positively for CD2,
CD45RO, and CD43 (a T cell markers) and for CD45 and CD79a (a B cell marker). In addition, many
proliferating T cells have been shown to express an additional marker
(CD56), which suggests an NK cell origin; these tumors are classified
as T/NK cell lymphomas , but they lack other NK cell markers, such as
CD16 and CD57.7,8
Radiological
imaging is vital in many aspects, including assessment of tumor extension,
bony destruction and choice of the best biopsy site and route and finally
for staging purposes. Although CT scan is the best technique to demonstrate
fine bony detail and should be considered the gold standard investigation,
MRI can adequately assess most areas of bony destruction and has additional
advantages in distinguishing a tumor from mucosal thickening or retained
sinus secretions. The CT imaging features of sinonasal lymphomas are
nonspecific. Common findings are bone destruction and invasion of adjacent
sinonasal cavities and orbits. The tumors are usually noncalcified and
demonstrated variable contrast enhancement. Because of the rarity of
the disease, there has been no consensus as to optimal management for
primary sinonasal lymphomas. NHLs are frequently treated with, and respond
to, a combination of chemotherapy and radiotherapy. A review of several
reports suggests that the best treatment outcomes are obtained with
the CHOP regimen, given at three-week intervals for six cycles.
Chemotherapy is frequently followed by loco-regional radiotherapy at
a dose of 30 to 40 Gy. Rituximab is a therapeutic antibody directed against the CD20 surface
antigen, which is frequently present in lymphoma cells. Its use in conjunction
with CHOP augments a treatment response in lymphomas expressing the
CD20 antigen.9 A large study reported that the use of combined
chemotherapy and radiation therapy significantly improved the five-year
disease-free survival and overall survival rates.10 Our patient
also received combined chemotherapy and radiation therapy, the sign
and symptoms were dramatically improved. Patients with sinonasal lymphomas
have a better prognosis than those with nodal and Waldayer’s lymphomas
of similar histological grades.8 Favorable prognostic factors
include a young age, diagnosis at an early stage of the disease, and
an absence of fever, weight loss, and night sweats. A large study done
in M.D. Anderson Cancer Center Houston, USA on 70 patients with lymphoma
of the nasal cavity and paranasal sinuses reported 5 year survival rate
of 52%.10
Lymphomas must always
be included in the differential diagnosis of the unilateral sinonasal
lesions. Early diagnosis
by histological analysis which is confirmed by immunohistochemistry
and appropriate staging by CT scan is essential in the management of
sinonasal NHL.
- Shohat I, Berkowicz
M, Dori S, Horowitz Z, Wolf M, Taicher S et al.
Primary non-Hodgkin’s lymphoma of the sinonasal tract. Oral Surg Oral
Med Oral Pathol 2004;97:328-31.
- Quraishi M, Bessel
E, Clark D, Jones N, Bradley P. Non Hodgkin’s lymphoma of the sinonasal
tract. Laryngoscope 2000;110:1489-92.
- Abbondanzo S, Wenig
B. Non Hodgkin’s lymphoma of the sinonasal tract.
Cancer
1995;75:1281-91.
- Harris N, Jaffe
E, Stein H, Banks P, Chan J, Cleary M et al. A revised European-American
classification of lymphoid neoplasms: a proposal from the International
Lymphoma Study Group. Blood 1994;84:1361-92.
- National Cancer
Institute sponsored study of classifications of non-Hodgkin’s lymphomas:
summary and description of a working formulation for clinical usage.
The non-Hodgkin’s lymphoma pathologic classification project. Cancer
1982;49:2112-35.
- Cheung MM, Chan
JK, Lau WH, Foo W, Chan PT, Ng CS et al. Primary non-Hodgkin’s lymphoma
of the nose and nasopharynx: clinical features,tumor immunophenotype
and treatment outcome in 113 patients. J clin Otol 1998:16:70-7
- Cleary KC, Batsakis
JG. Sinonasal lymphomas. Ann Otol Rhinol Laryngol 1994;103:911-4.
- Vidal RW, Devaney
K, Ferlito A et al. Sinonasal malignant lymphomas: A distinct clinicopathological
category. Ann Otol Rhinol Laryngol 1999;108:411-19.
- Nakamura K, Uehara
S, Omagari J, Kunitake N, Kimura M, Makino Y, Ishigami K, Masuda K.
Primary non-Hodgkin lymphoma of the sinonasal cavities: correlation
of CT evaluation with clinical outcome.
Radiology 1997;204:431-435
- Longsdon M, Ha
C, Kavadi V, Cabanillas F, Hess M, Cox J. Lymphoma of the nasal cavity
and paranasal sinuses. Improved outcome and altered prognostic factors
with combined modality therapy. Cancer 1997;80:477-88.
|